Krayenbuehl Pierre-Alexandre, Maly Friedrich E, Hersberger Martin, Wiesli Peter, Himmelmann Andreas, Eid Karim, Greminger Peter, Vetter Wilhelm, Schulthess Georg
Medical Policlinic, Department of Internal Medicine, University Hospital of Zurich, Switzerland.
Clin Chem. 2006 Aug;52(8):1552-8. doi: 10.1373/clinchem.2005.065417. Epub 2006 Jun 22.
In vitro and animal studies suggest that tumor necrosis factor alpha (TNF-alpha) modulates intestinal iron transport. We hypothesized that the effect of TNF-alpha might be particularly relevant if iron absorption is not effectively controlled by the HFE gene.
In patients with homozygous C282Y hemochromatosis, we investigated the influence of TNF-alpha -308G>A allelic variant on total body iron overload, determined in all patients by measuring iron removed during depletion therapy, and hepatic iron index and need for phlebotomy to prevent iron reaccumulation, measured in patient subgroups.
Of 86 patients with hereditary hemochromatosis, 16 (19%) were heterozygous carriers and 1 (1%) was a homozygous carrier of the TNF-alpha promoter -308A allele. Mean (SD) total body iron overload was increased 2-fold in TNF-alpha -308A allele carriers [10.9 (7.6) g] compared with homozygous carriers of the G allele [5.6 (5.0) g, P<0.001]. Hepatic iron index differed markedly between TNF-alpha -308A allele carriers [5.6 (3.5) micromol/g/year] and homozygous G allele carriers [3.1 (2.2) micromol/g/year, P=0.040, n=30]. After iron depletion, the need for phlebotomy to prevent iron reaccumulation (maintenance therapy) was substantially higher in TNF-alpha -308A allele carriers than in homozygous G allele carriers (P=0.014, n=73). We used multiple regression analyses to exclude possible confounding effects of sex, age, family screening, body-mass index, and meat or alcohol intake.
TNF-alpha -308G>A allelic variant modulates iron accumulation in patients with hereditary (homozygous C282Y) hemochromatosis, but the effect of the TNF-alpha -308A allele on clinical manifestations of hemochromatosis was less accentuated than expected from the increased iron load associated with this allele.
体外及动物研究表明,肿瘤坏死因子α(TNF-α)可调节肠道铁转运。我们推测,如果铁吸收未受HFE基因有效控制,TNF-α的作用可能尤为重要。
在纯合C282Y型血色素沉着症患者中,我们研究了TNF-α -308G>A等位基因变异对全身铁过载的影响,所有患者均通过测量去铁治疗期间去除的铁来确定全身铁过载情况,在患者亚组中测量肝铁指数及防止铁再蓄积所需的放血治疗需求。
在86例遗传性血色素沉着症患者中,16例(19%)为TNF-α启动子-308A等位基因的杂合携带者;其中1例(1%)为该等位基因的纯合携带者。与G等位基因纯合携带者[5.6(5.0)g,P<0.001]相比,TNF-α -308A等位基因携带者的平均(标准差)全身铁过载增加了2倍[10.9(7.6)g]。TNF-α -308A等位基因携带者[5.6(3.5)μmol/g/年]与G等位基因纯合携带者[3.1(2.2)μmol/g/年,P = 0.040,n = 30]的肝铁指数有显著差异。铁去除后,TNF-α -308A等位基因携带者防止铁再蓄积(维持治疗)所需的放血治疗需求显著高于G等位基因纯合携带者(P = 0.014,n = 73)。我们采用多元回归分析排除了性别、年龄、家族筛查、体重指数以及肉类或酒精摄入量等可能的混杂影响。
TNF-α -308G>A等位基因变异可调节遗传性(纯合C282Y型)血色素沉着症患者的铁蓄积,但TNF-α -308A等位基因对血色素沉着症临床表现的影响不如该等位基因相关的铁负荷增加所预期的那样显著。